世界の免疫性血小板減少症治療薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Immune Thrombocytopenia Drugs Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-5797 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、99ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、免疫性血小板減少症治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（トロンボポエチン受容体作動薬 (TPO-RAs)、コルチコステロイド、静脈免疫グロブリン (IVIGs)、その他薬剤）、用途別市場規模（バイオテクノロジー＆製薬会社、病院＆診断センター、学術機関＆研究機関）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・免疫性血小板減少症治療薬の市場動向 ・企業の競争状況、市場シェア ・免疫性血小板減少症治療薬の種類別市場規模と予測2016-2027（トロンボポエチン受容体作動薬 (TPO-RAs)、コルチコステロイド、静脈免疫グロブリン (IVIGs)、その他薬剤） ・免疫性血小板減少症治療薬の用途別市場規模と予測2016-2027（バイオテクノロジー＆製薬会社、病院＆診断センター、学術機関＆研究機関） ・免疫性血小板減少症治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・免疫性血小板減少症治療薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・免疫性血小板減少症治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・免疫性血小板減少症治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・免疫性血小板減少症治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Amgen Inc.、CSL Ltd.、Horizon Therapeutics Plc、Merck & Co., Inc.、Novartis AG、Rigel Pharmaceuticals Inc.） ・結論

Thrombocytopenia is a condition characterized by abnormally low levels of thrombocytes, also known as platelets, in the blood.
End-users prefer biosimilars over biologics because of their low cost. The low cost of biosimilars can be attributed to the fewer number of clinical trials required for approval. The upcoming expiration of patents in the immune thrombocytopenia drugs market will fuel the development of biosimilars for those products. For instance, the forthcoming expiration of patents of Nplate (romiplostim) and rituximab has encouraged market vendors to develop their biosimilars. This will also create several opportunities for new vendors to enter the market. Hence, the growing popularity and development of biosimilars will augment the growth of the immune thrombocytopenia drugs market throughout the next five years.

Market Analysis and Insights: Global Immune Thrombocytopenia Drugs Market
The global Immune Thrombocytopenia Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Immune Thrombocytopenia Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Immune Thrombocytopenia Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Immune Thrombocytopenia Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Immune Thrombocytopenia Drugs market.

Global Immune Thrombocytopenia Drugs Scope and Market Size
Immune Thrombocytopenia Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Immune Thrombocytopenia Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Thrombopoietin Receptor Agonists (TPO-RAs)
Corticosteroids
Intravenous Immunoglobins (IVIGs)
Other Drugs

Segment by Application
Biotechnology and Pharmaceutical Companies
Hospitals and Diagnostic Centers
Academic Institutes and Research Organizations

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Amgen Inc.
CSL Ltd.
Horizon Therapeutics Plc
Merck & Co., Inc.
Novartis AG
Rigel Pharmaceuticals Inc.

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Immune Thrombocytopenia Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Thrombopoietin Receptor Agonists (TPO-RAs)
1.2.3 Corticosteroids
1.2.4 Intravenous Immunoglobins (IVIGs)
1.2.5 Other Drugs
1.3 Market by Application
1.3.1 Global Immune Thrombocytopenia Drugs Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Biotechnology and Pharmaceutical Companies
1.3.3 Hospitals and Diagnostic Centers
1.3.4 Academic Institutes and Research Organizations
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Immune Thrombocytopenia Drugs Market Perspective (2016-2027)
2.2 Immune Thrombocytopenia Drugs Growth Trends by Regions
2.2.1 Immune Thrombocytopenia Drugs Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Immune Thrombocytopenia Drugs Historic Market Share by Regions (2016-2021)
2.2.3 Immune Thrombocytopenia Drugs Forecasted Market Size by Regions (2022-2027)
2.3 Immune Thrombocytopenia Drugs Industry Dynamic
2.3.1 Immune Thrombocytopenia Drugs Market Trends
2.3.2 Immune Thrombocytopenia Drugs Market Drivers
2.3.3 Immune Thrombocytopenia Drugs Market Challenges
2.3.4 Immune Thrombocytopenia Drugs Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Immune Thrombocytopenia Drugs Players by Revenue
3.1.1 Global Top Immune Thrombocytopenia Drugs Players by Revenue (2016-2021)
3.1.2 Global Immune Thrombocytopenia Drugs Revenue Market Share by Players (2016-2021)
3.2 Global Immune Thrombocytopenia Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Immune Thrombocytopenia Drugs Revenue
3.4 Global Immune Thrombocytopenia Drugs Market Concentration Ratio
3.4.1 Global Immune Thrombocytopenia Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Immune Thrombocytopenia Drugs Revenue in 2020
3.5 Immune Thrombocytopenia Drugs Key Players Head office and Area Served
3.6 Key Players Immune Thrombocytopenia Drugs Product Solution and Service
3.7 Date of Enter into Immune Thrombocytopenia Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Immune Thrombocytopenia Drugs Breakdown Data by Type
4.1 Global Immune Thrombocytopenia Drugs Historic Market Size by Type (2016-2021)
4.2 Global Immune Thrombocytopenia Drugs Forecasted Market Size by Type (2022-2027)

5 Immune Thrombocytopenia Drugs Breakdown Data by Application
5.1 Global Immune Thrombocytopenia Drugs Historic Market Size by Application (2016-2021)
5.2 Global Immune Thrombocytopenia Drugs Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Immune Thrombocytopenia Drugs Market Size (2016-2027)
6.2 North America Immune Thrombocytopenia Drugs Market Size by Type
6.2.1 North America Immune Thrombocytopenia Drugs Market Size by Type (2016-2021)
6.2.2 North America Immune Thrombocytopenia Drugs Market Size by Type (2022-2027)
6.2.3 North America Immune Thrombocytopenia Drugs Market Size by Type (2016-2027)
6.3 North America Immune Thrombocytopenia Drugs Market Size by Application
6.3.1 North America Immune Thrombocytopenia Drugs Market Size by Application (2016-2021)
6.3.2 North America Immune Thrombocytopenia Drugs Market Size by Application (2022-2027)
6.3.3 North America Immune Thrombocytopenia Drugs Market Size by Application (2016-2027)
6.4 North America Immune Thrombocytopenia Drugs Market Size by Country
6.4.1 North America Immune Thrombocytopenia Drugs Market Size by Country (2016-2021)
6.4.2 North America Immune Thrombocytopenia Drugs Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Immune Thrombocytopenia Drugs Market Size (2016-2027)
7.2 Europe Immune Thrombocytopenia Drugs Market Size by Type
7.2.1 Europe Immune Thrombocytopenia Drugs Market Size by Type (2016-2021)
7.2.2 Europe Immune Thrombocytopenia Drugs Market Size by Type (2022-2027)
7.2.3 Europe Immune Thrombocytopenia Drugs Market Size by Type (2016-2027)
7.3 Europe Immune Thrombocytopenia Drugs Market Size by Application
7.3.1 Europe Immune Thrombocytopenia Drugs Market Size by Application (2016-2021)
7.3.2 Europe Immune Thrombocytopenia Drugs Market Size by Application (2022-2027)
7.3.3 Europe Immune Thrombocytopenia Drugs Market Size by Application (2016-2027)
7.4 Europe Immune Thrombocytopenia Drugs Market Size by Country
7.4.1 Europe Immune Thrombocytopenia Drugs Market Size by Country (2016-2021)
7.4.2 Europe Immune Thrombocytopenia Drugs Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Immune Thrombocytopenia Drugs Market Size (2016-2027)
8.2 Asia-Pacific Immune Thrombocytopenia Drugs Market Size by Type
8.2.1 Asia-Pacific Immune Thrombocytopenia Drugs Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Immune Thrombocytopenia Drugs Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Immune Thrombocytopenia Drugs Market Size by Type (2016-2027)
8.3 Asia-Pacific Immune Thrombocytopenia Drugs Market Size by Application
8.3.1 Asia-Pacific Immune Thrombocytopenia Drugs Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Immune Thrombocytopenia Drugs Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Immune Thrombocytopenia Drugs Market Size by Application (2016-2027)
8.4 Asia-Pacific Immune Thrombocytopenia Drugs Market Size by Region
8.4.1 Asia-Pacific Immune Thrombocytopenia Drugs Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Immune Thrombocytopenia Drugs Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Immune Thrombocytopenia Drugs Market Size (2016-2027)
9.2 Latin America Immune Thrombocytopenia Drugs Market Size by Type
9.2.1 Latin America Immune Thrombocytopenia Drugs Market Size by Type (2016-2021)
9.2.2 Latin America Immune Thrombocytopenia Drugs Market Size by Type (2022-2027)
9.2.3 Latin America Immune Thrombocytopenia Drugs Market Size by Type (2016-2027)
9.3 Latin America Immune Thrombocytopenia Drugs Market Size by Application
9.3.1 Latin America Immune Thrombocytopenia Drugs Market Size by Application (2016-2021)
9.3.2 Latin America Immune Thrombocytopenia Drugs Market Size by Application (2022-2027)
9.3.3 Latin America Immune Thrombocytopenia Drugs Market Size by Application (2016-2027)
9.4 Latin America Immune Thrombocytopenia Drugs Market Size by Country
9.4.1 Latin America Immune Thrombocytopenia Drugs Market Size by Country (2016-2021)
9.4.2 Latin America Immune Thrombocytopenia Drugs Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Immune Thrombocytopenia Drugs Market Size (2016-2027)
10.2 Middle East & Africa Immune Thrombocytopenia Drugs Market Size by Type
10.2.1 Middle East & Africa Immune Thrombocytopenia Drugs Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Immune Thrombocytopenia Drugs Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Immune Thrombocytopenia Drugs Market Size by Type (2016-2027)
10.3 Middle East & Africa Immune Thrombocytopenia Drugs Market Size by Application
10.3.1 Middle East & Africa Immune Thrombocytopenia Drugs Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Immune Thrombocytopenia Drugs Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Immune Thrombocytopenia Drugs Market Size by Application (2016-2027)
10.4 Middle East & Africa Immune Thrombocytopenia Drugs Market Size by Country
10.4.1 Middle East & Africa Immune Thrombocytopenia Drugs Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Immune Thrombocytopenia Drugs Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Amgen Inc.
11.1.1 Amgen Inc. Company Details
11.1.2 Amgen Inc. Business Overview
11.1.3 Amgen Inc. Immune Thrombocytopenia Drugs Introduction
11.1.4 Amgen Inc. Revenue in Immune Thrombocytopenia Drugs Business (2016-2021)
11.1.5 Amgen Inc. Recent Development
11.2 CSL Ltd.
11.2.1 CSL Ltd. Company Details
11.2.2 CSL Ltd. Business Overview
11.2.3 CSL Ltd. Immune Thrombocytopenia Drugs Introduction
11.2.4 CSL Ltd. Revenue in Immune Thrombocytopenia Drugs Business (2016-2021)
11.2.5 CSL Ltd. Recent Development
11.3 Horizon Therapeutics Plc
11.3.1 Horizon Therapeutics Plc Company Details
11.3.2 Horizon Therapeutics Plc Business Overview
11.3.3 Horizon Therapeutics Plc Immune Thrombocytopenia Drugs Introduction
11.3.4 Horizon Therapeutics Plc Revenue in Immune Thrombocytopenia Drugs Business (2016-2021)
11.3.5 Horizon Therapeutics Plc Recent Development
11.4 Merck & Co., Inc.
11.4.1 Merck & Co., Inc. Company Details
11.4.2 Merck & Co., Inc. Business Overview
11.4.3 Merck & Co., Inc. Immune Thrombocytopenia Drugs Introduction
11.4.4 Merck & Co., Inc. Revenue in Immune Thrombocytopenia Drugs Business (2016-2021)
11.4.5 Merck & Co., Inc. Recent Development
11.5 Novartis AG
11.5.1 Novartis AG Company Details
11.5.2 Novartis AG Business Overview
11.5.3 Novartis AG Immune Thrombocytopenia Drugs Introduction
11.5.4 Novartis AG Revenue in Immune Thrombocytopenia Drugs Business (2016-2021)
11.5.5 Novartis AG Recent Development
11.6 Rigel Pharmaceuticals Inc.
11.6.1 Rigel Pharmaceuticals Inc. Company Details
11.6.2 Rigel Pharmaceuticals Inc. Business Overview
11.6.3 Rigel Pharmaceuticals Inc. Immune Thrombocytopenia Drugs Introduction
11.6.4 Rigel Pharmaceuticals Inc. Revenue in Immune Thrombocytopenia Drugs Business (2016-2021)
11.6.5 Rigel Pharmaceuticals Inc. Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Immune Thrombocytopenia Drugs Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Thrombopoietin Receptor Agonists (TPO-RAs)
Table 3. Key Players of Corticosteroids
Table 4. Key Players of Intravenous Immunoglobins (IVIGs)
Table 5. Key Players of Other Drugs
Table 6. Global Immune Thrombocytopenia Drugs Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Immune Thrombocytopenia Drugs Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Immune Thrombocytopenia Drugs Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Immune Thrombocytopenia Drugs Market Share by Regions (2016-2021)
Table 10. Global Immune Thrombocytopenia Drugs Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Immune Thrombocytopenia Drugs Market Share by Regions (2022-2027)
Table 12. Immune Thrombocytopenia Drugs Market Trends
Table 13. Immune Thrombocytopenia Drugs Market Drivers
Table 14. Immune Thrombocytopenia Drugs Market Challenges
Table 15. Immune Thrombocytopenia Drugs Market Restraints
Table 16. Global Immune Thrombocytopenia Drugs Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Immune Thrombocytopenia Drugs Market Share by Players (2016-2021)
Table 18. Global Top Immune Thrombocytopenia Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Immune Thrombocytopenia Drugs as of 2020)
Table 19. Ranking of Global Top Immune Thrombocytopenia Drugs Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Immune Thrombocytopenia Drugs Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Immune Thrombocytopenia Drugs Product Solution and Service
Table 23. Date of Enter into Immune Thrombocytopenia Drugs Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Immune Thrombocytopenia Drugs Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Immune Thrombocytopenia Drugs Revenue Market Share by Type (2016-2021)
Table 27. Global Immune Thrombocytopenia Drugs Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Immune Thrombocytopenia Drugs Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Immune Thrombocytopenia Drugs Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Immune Thrombocytopenia Drugs Revenue Market Share by Application (2016-2021)
Table 31. Global Immune Thrombocytopenia Drugs Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Immune Thrombocytopenia Drugs Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Immune Thrombocytopenia Drugs Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Immune Thrombocytopenia Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Immune Thrombocytopenia Drugs Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Immune Thrombocytopenia Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Immune Thrombocytopenia Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Immune Thrombocytopenia Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Immune Thrombocytopenia Drugs Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Immune Thrombocytopenia Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Immune Thrombocytopenia Drugs Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Immune Thrombocytopenia Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Immune Thrombocytopenia Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Immune Thrombocytopenia Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Immune Thrombocytopenia Drugs Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Immune Thrombocytopenia Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Immune Thrombocytopenia Drugs Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Immune Thrombocytopenia Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Immune Thrombocytopenia Drugs Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Immune Thrombocytopenia Drugs Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Immune Thrombocytopenia Drugs Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Immune Thrombocytopenia Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Immune Thrombocytopenia Drugs Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Immune Thrombocytopenia Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Immune Thrombocytopenia Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Immune Thrombocytopenia Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Immune Thrombocytopenia Drugs Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Immune Thrombocytopenia Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Immune Thrombocytopenia Drugs Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Immune Thrombocytopenia Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Immune Thrombocytopenia Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Immune Thrombocytopenia Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 63. Amgen Inc. Company Details
Table 64. Amgen Inc. Business Overview
Table 65. Amgen Inc. Immune Thrombocytopenia Drugs Product
Table 66. Amgen Inc. Revenue in Immune Thrombocytopenia Drugs Business (2016-2021) & (US$ Million)
Table 67. Amgen Inc. Recent Development
Table 68. CSL Ltd. Company Details
Table 69. CSL Ltd. Business Overview
Table 70. CSL Ltd. Immune Thrombocytopenia Drugs Product
Table 71. CSL Ltd. Revenue in Immune Thrombocytopenia Drugs Business (2016-2021) & (US$ Million)
Table 72. CSL Ltd. Recent Development
Table 73. Horizon Therapeutics Plc Company Details
Table 74. Horizon Therapeutics Plc Business Overview
Table 75. Horizon Therapeutics Plc Immune Thrombocytopenia Drugs Product
Table 76. Horizon Therapeutics Plc Revenue in Immune Thrombocytopenia Drugs Business (2016-2021) & (US$ Million)
Table 77. Horizon Therapeutics Plc Recent Development
Table 78. Merck & Co., Inc. Company Details
Table 79. Merck & Co., Inc. Business Overview
Table 80. Merck & Co., Inc. Immune Thrombocytopenia Drugs Product
Table 81. Merck & Co., Inc. Revenue in Immune Thrombocytopenia Drugs Business (2016-2021) & (US$ Million)
Table 82. Merck & Co., Inc. Recent Development
Table 83. Novartis AG Company Details
Table 84. Novartis AG Business Overview
Table 85. Novartis AG Immune Thrombocytopenia Drugs Product
Table 86. Novartis AG Revenue in Immune Thrombocytopenia Drugs Business (2016-2021) & (US$ Million)
Table 87. Novartis AG Recent Development
Table 88. Rigel Pharmaceuticals Inc. Company Details
Table 89. Rigel Pharmaceuticals Inc. Business Overview
Table 90. Rigel Pharmaceuticals Inc. Immune Thrombocytopenia Drugs Product
Table 91. Rigel Pharmaceuticals Inc. Revenue in Immune Thrombocytopenia Drugs Business (2016-2021) & (US$ Million)
Table 92. Rigel Pharmaceuticals Inc. Recent Development
Table 93. Research Programs/Design for This Report
Table 94. Key Data Information from Secondary Sources
Table 95. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Immune Thrombocytopenia Drugs Market Share by Type: 2020 VS 2027
Figure 2. Thrombopoietin Receptor Agonists (TPO-RAs) Features
Figure 3. Corticosteroids Features
Figure 4. Intravenous Immunoglobins (IVIGs) Features
Figure 5. Other Drugs Features
Figure 6. Global Immune Thrombocytopenia Drugs Market Share by Application: 2020 VS 2027
Figure 7. Biotechnology and Pharmaceutical Companies Case Studies
Figure 8. Hospitals and Diagnostic Centers Case Studies
Figure 9. Academic Institutes and Research Organizations Case Studies
Figure 10. Immune Thrombocytopenia Drugs Report Years Considered
Figure 11. Global Immune Thrombocytopenia Drugs Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Immune Thrombocytopenia Drugs Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Immune Thrombocytopenia Drugs Market Share by Regions: 2020 VS 2027
Figure 14. Global Immune Thrombocytopenia Drugs Market Share by Regions (2022-2027)
Figure 15. Global Immune Thrombocytopenia Drugs Market Share by Players in 2020
Figure 16. Global Top Immune Thrombocytopenia Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Immune Thrombocytopenia Drugs as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Immune Thrombocytopenia Drugs Revenue in 2020
Figure 18. Global Immune Thrombocytopenia Drugs Revenue Market Share by Type (2016-2021)
Figure 19. Global Immune Thrombocytopenia Drugs Revenue Market Share by Type (2022-2027)
Figure 20. North America Immune Thrombocytopenia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Immune Thrombocytopenia Drugs Market Share by Type (2016-2027)
Figure 22. North America Immune Thrombocytopenia Drugs Market Share by Application (2016-2027)
Figure 23. North America Immune Thrombocytopenia Drugs Market Share by Country (2016-2027)
Figure 24. United States Immune Thrombocytopenia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Immune Thrombocytopenia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Immune Thrombocytopenia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Immune Thrombocytopenia Drugs Market Share by Type (2016-2027)
Figure 28. Europe Immune Thrombocytopenia Drugs Market Share by Application (2016-2027)
Figure 29. Europe Immune Thrombocytopenia Drugs Market Share by Country (2016-2027)
Figure 30. Germany Immune Thrombocytopenia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Immune Thrombocytopenia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Immune Thrombocytopenia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Immune Thrombocytopenia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Immune Thrombocytopenia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Immune Thrombocytopenia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Immune Thrombocytopenia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Immune Thrombocytopenia Drugs Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Immune Thrombocytopenia Drugs Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Immune Thrombocytopenia Drugs Market Share by Region (2016-2027)
Figure 40. China Immune Thrombocytopenia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Immune Thrombocytopenia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Immune Thrombocytopenia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Immune Thrombocytopenia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Immune Thrombocytopenia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Immune Thrombocytopenia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Immune Thrombocytopenia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Immune Thrombocytopenia Drugs Market Share by Type (2016-2027)
Figure 48. Latin America Immune Thrombocytopenia Drugs Market Share by Application (2016-2027)
Figure 49. Latin America Immune Thrombocytopenia Drugs Market Share by Country (2016-2027)
Figure 50. Mexico Immune Thrombocytopenia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Immune Thrombocytopenia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Immune Thrombocytopenia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Immune Thrombocytopenia Drugs Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Immune Thrombocytopenia Drugs Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Immune Thrombocytopenia Drugs Market Share by Country (2016-2027)
Figure 56. Turkey Immune Thrombocytopenia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Immune Thrombocytopenia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Immune Thrombocytopenia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Amgen Inc. Revenue Growth Rate in Immune Thrombocytopenia Drugs Business (2016-2021)
Figure 60. CSL Ltd. Revenue Growth Rate in Immune Thrombocytopenia Drugs Business (2016-2021)
Figure 61. Horizon Therapeutics Plc Revenue Growth Rate in Immune Thrombocytopenia Drugs Business (2016-2021)
Figure 62. Merck & Co., Inc. Revenue Growth Rate in Immune Thrombocytopenia Drugs Business (2016-2021)
Figure 63. Novartis AG Revenue Growth Rate in Immune Thrombocytopenia Drugs Business (2016-2021)
Figure 64. Rigel Pharmaceuticals Inc. Revenue Growth Rate in Immune Thrombocytopenia Drugs Business (2016-2021)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed

---